Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
← All stories
Federal PolicyNovember 17, 2026

FDA Grants Accelerated Approval to Nuvalent's ALK Lung Cancer Drug

The FDA granted accelerated approval on Nov. 17 to Nuvalent's Nelkarmi (neladalkib) for adults with previously treated, locally advanced or metastatic ALK-positive non-small cell lung cancer. The drug is approved for patients who previously received alectinib as their only ALK inhibitor, or at least two ALK inhibitors plus platinum-based chemotherapy. Approval was based on the phase 1/2 ALKOVE-1 trial, where response rates were 49% among alectinib-pretreated patients and 32% among those with prior multiple ALK inhibitors and chemotherapy. The prescribing information warns of liver, kidney and eye toxicity, elevated creatine phosphokinase, and embryo-fetal toxicity; the recommended dose is 150 mg orally once daily. The application received priority review, breakthrough therapy, and orphan drug designations.

Why it mattersMedicaid pharmacy programs and managed care plans covering beneficiaries with ALK-positive lung cancer may need to update formularies and prior authorization criteria to account for this newly approved treatment option.

Pharmacy

Read the full article at beckershospitalreview.com →
Share this briefing

You might also like

← All stories

Get the daily briefing.